Literature DB >> 7557857

Role of hepatitis C virus in dual and triple hepatitis virus infection.

Y F Liaw1.   

Abstract

Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) share same transmission routes, thus dual or triple infection may occur and even persist in the same patients. A significant amount of literature has accumulated since the advent of HCV assays. It is pertinent to review and evaluate the clinical and virological significance of HCV in multiple hepatotropic viral infection. The reported series on seroprevalence of HCV indicate that HCV is found in more than 10% of HBV- or HDV-infected patients worldwide. Of the patients with dual or triple infection involving HCV, those having coreplication of viruses tend to have severe and progressive liver disease that is resistant to interferon therapy, in contrast with patients having a single virus infection. Paradoxically, dual or triple hepatitis virus infections are associated with viral interference. In particular, HCV exerts a suppressive effect on HBV and HDV and may enhance seroclearance of HBV antigens or even usurp the role of preexisting virus as the agent for continuing hepatitis. Although HBV and HDV may also suppress HCV, it appears to be less effective. These findings clearly suggest the necessity of monitoring patients with HBV or HDV infections. In view of complex dynamism of viral interaction in multiple hepatotropic virus infection, the importance of HCV assay in the clinical studies can not be overemphasized. The basic mechanisms that regulate the viral interactions, in particular the impact of HCV in dual or triple virus infections, remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557857     DOI: 10.1016/0270-9139(95)90615-0

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses.

Authors:  T Laskus; M Radkowski; L F Wang; H Vargas; J Rakela
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function.

Authors:  Zhi Qiang Yao; Stephen N Waggoner; Michael W Cruise; Caroline Hall; Xuefang Xie; David W Oldach; Young S Hahn
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 3.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

Review 4.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

6.  Causal Mediation Analysis of Survival Outcome with Multiple Mediators.

Authors:  Yen-Tsung Huang; Hwai-I Yang
Journal:  Epidemiology       Date:  2017-05       Impact factor: 4.822

7.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 8.  Regulatory mechanisms of viral hepatitis B and C.

Authors:  G Waris; A Siddiqui
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV.

Authors:  C-M Chu; C T Yeh; I S Sheen; Y F Liaw
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence.

Authors:  F H Pujol; J G Ponce; M G Lema; F Capriles; M Devesa; F Sirit; M Salazar; G Vásquez; F Monsalve; L Blitz-Dorfman
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.